CENTOGENE N.V., Am Strande 7, 18055 Rostock, Germany

 

U.S. Securities and Exchange Commission
100 F Street, N.E.
Washington, D.C. 20549

United States

 

April 23, 2020

 

Re:               Notice of disclosure filed in Exchange Act Annual Report under Section 219 of the Iran Threat Reduction and Syria Human Rights Act of 2012 and Section 13(r) of the Exchange Act

 

Ladies and Gentlemen,

 

Pursuant to Section 219 of the Iran Threat Reduction and Syria Human Rights Act of 2012 and Section 13(r) of the Securities Exchange Act of 1934, as amended, notice is hereby provided that Centogene N.V. made disclosure pursuant to those provisions in its Annual Report on Form 20-F for the year ended December 31, 2019, which was filed with the Securities and Exchange Commission on April 23, 2020. The disclosure can be found under the heading “Miscellaneous— Disclosure under Iran Threat Reduction and Syria Human Rights Act of 2012 (ITRA)” in the Annual Report on Form 20-F.

 

Respectfully submitted,

 

 

/s/ Arndt Rolfs

 

Arndt Rolfs

 

Chief Executive Officer

 

Centogene N.V.

 

 

CENTOGENE N.V.

Management Board:

Statutory seat:

Am Strande 7

Prof. Dr. Arndt Rolfs (CEO)

Amsterdam, registered with the Kamer van

18055 Rostock, Germany

Richard Stoffelen (CFO)

Koophandel (Netherlands) under 72822872

Tel: +49 (0)381 80 113 - 400

Dr. Volkmar Weckesser (CIO)

Bank account details:

Fax: +49 (0)381 80 113 - 401

Dr. Dirk Ehlers (COO)

Bank: Commerzbank AG

Email: info@centogene.com

Supervisory Board:

IBAN: DE60130400000108866500

www.centogene.com

Dr. Flemming Ornskov (Chairman)

BIC: COBADEFFXXX